WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Development of Plant-Based Edible Vaccines for Global Health Applications

***Armaan Samsuddin Khan*[1]**

IDEAL INSTITUTE OF PHARMACY, POSHERI, WADA, MAHARASHTRA, INDIA, MUMBAI UNIVERSITY

ABSTRACT :

Plant-based edible vaccines represent a transformative, low-cost platform for global immunization, particularly in regions with limited healthcare infrastructure. This study explores the development, expression, and potential public-health applications of antigen-producing transgenic plants as an alternative to conventional vaccine systems. Using genetic engineering techniques, target antigen genes are inserted into suitable plant hosts mainly such as potatoes, tomatoes, bananas, and lettuce; to enable in-situ synthesis of immunogenic proteins. When consumed, these plant tissues can stimulate both mucosal and systemic immune responses, eliminating the need for cold-chain storage, sterile injections, and specialized medical personnel. The present work evaluates expression stability, dosage consistency, bioavailability, and immunogenicity of these edible vaccine candidates, alongside an assessment of biosafety concerns and scalability. Findings highlight the promise of plant-derived vaccines in addressing infectious diseases like hepatitis B, cholera, and diarrheal diseases, while emphasizing the need for improved expression systems and rigorous clinical validation. Overall, plant-based edible vaccines emerge as an innovative, accessible, and globally deployable tool to strengthen public health and reduce vaccine inequity.

INTRODUCTION

Vaccination remains one of the most effective public-health interventions for controlling infectious diseases. However, traditional vaccine platforms face persistent challenges, including high production costs, dependence on cold-chain storage, needle-based delivery, and the requirement for trained healthcare personnel. These limitations disproportionately affect low- and middle-income countries, where logistical barriers often restrict timely and equitable immunization.

In recent years, plant biotechnology has emerged as a promising alternative for vaccine development, offering a cost-effective, scalable, and environmentally sustainable production system. Plant-based edible vaccines harness the ability of genetically engineered plants to express antigenic proteins that, when consumed, can activate mucosal and systemic immunity. Unlike conventional vaccines, edible vaccines eliminate barriers associated with manufacturing and distribution, as plants can be grown locally, require minimal infrastructure, and inherently encapsulate antigens in plant cells, improving stability during storage and digestion.

Research over the past two decades has demonstrated the feasibility of expressing clinically relevant antigens in common crops such as potatoes, tomatoes, bananas, lettuce, and rice. These systems have shown potential in combating diseases including hepatitis B, cholera, Norwalk virus infection, and various enteric pathogens. Despite these advances, challenges remain particularly in achieving consistent antigen dosage, ensuring expression stability across generations, and meeting stringent regulatory standards for genetically modified organisms.

As global health priorities shift toward accessible and scalable vaccine technologies, plant-based edible vaccines stand out as a forward-looking solution capable of reducing vaccine inequity and strengthening pandemic preparedness. This review examines their development process, immunological potential, biosafety considerations, and opportunities for real-world application in global health initiatives.

PLANT-BASED VACCINE DEVELOPMENT AND MECHANISM OF ACTION

Edible vaccines are produced by incorporating genes encoding specific antigens into plant tissues using Agrobacterium-mediated transformation or biolistic gene-delivery methods. Once integrated, the plant cellular machinery expresses the antigenic protein in edible tissues.

When these tissues are consumed, the antigen is released in the gastrointestinal tract, where it is processed by mucosal immune cells in Peyer's patches. This stimulates both humoral (IgG) and mucosal (IgA) immune responses, mimicking natural infection pathways and providing broad-spectrum immunity.

Key advantages include:

- Needle-free administration
- Reduced production and storage costs
- Elimination of cold-chain dependence
- Lower risk of contamination
- Ease of mass production in agricultural settings

However, antigen degradation in the digestive tract and variable uptake remain core challenges that require optimized plant expression systems and improved antigen-stabilization strategies.

TRANSGENIC PLANTS USED FOR EDIBLE VACCINES

A variety of plant species serve as expression platforms for edible vaccines. Each offers unique advantages in terms of yield, palatability, and suitability for mass cultivation.

Potatoes

One of the earliest crops used in edible vaccine research. Potatoes efficiently express bacterial and viral antigens, though their consumption requires cooking, which can reduce antigenic stability.

Tomatoes

Tomatoes offer higher antigen expression and are consumed raw, making them ideal for mucosal-delivery vaccines. Their shorter growth cycle supports rapid production during outbreaks.

Bananas

Bananas provide an excellent medium for pediatric vaccines due to their natural sweetness, soft texture, and widespread consumption. However, long growth cycles and agricultural requirements pose limitations.

Lettuce

Lettuce allows rapid growth and high antigen stability while enabling controlled indoor cultivation. It is suitable for oral vaccines requiring higher dosage accuracy.

Rice and Maize

Cereals support long-term antigen stability due to their storage proteins. They are ideal for large-scale distribution in regions lacking refrigeration.

Figure 1: Conceptual representation of antigen expression in transgenic plants



Figure 2: Illustration of mucosal immune activation following edible vaccine intake



IMMUNOLOGICAL RESPONSE AND EFFICACY

Edible vaccines primarily target the mucosal immune system, which acts as the first line of defense against many pathogens.
Upon ingestion:

- Antigens are transported across intestinal epithelial cells.
- Dendritic cells and M cells process the antigen.
- Activation of T cells and B cells occurs in Peyer's patches.
- Secretory IgA and systemic IgG are produced.

Studies demonstrate that edible vaccines expressing antigens from hepatitis B surface protein, cholera toxin B subunit, and Norwalk virus can generate strong mucosal immunity in preclinical and early clinical trials. Co-expression with adjuvants, such as cytokines or heat-labile enterotoxin components, further enhances immune responses.

BIOSAFETY, REGULATORY, AND ETHICAL CONSIDERATIONS

Despite significant promise, edible vaccines face several regulatory and biosafety challenges:

- Risk of unintentional gene flow to non-transgenic crops
- Difficulty in standardizing antigen doses in fresh produce
- Public concern regarding genetically modified organisms
- Need for strict segregation, labeling, and traceability in agricultural settings

Regulatory agencies emphasize stringent clinical evaluations, environmental risk assessments, and controlled cultivation systems to ensure safety and efficacy.

CURRENT APPLICATIONS IN GLOBAL HEALTH

Edible vaccines are being explored for diseases disproportionately affecting low-income regions:

- **Hepatitis B** – Transgenic potato and lettuce prototypes show promising antibody responses.
- **Cholera** – Cholera toxin B (CTB)-expressing plants demonstrate strong mucosal immunity.
- **Diarrheal diseases** – Edible vaccines targeting enterotoxigenic E. coli (ETEC) help reduce childhood mortality.
- **Norwalk virus** – One of the earliest successful human trials using transgenic tomatoes.

Their low cost, simplified logistics, and heat stability make them especially valuable for remote and underserved populations.

EMERGING TECHNOLOGIES AND FUTURE DIRECTIONS

Advancements improving edible vaccine development include:

- Chloroplast transformation for higher antigen yield
- CRISPR/Cas-based precision gene insertion
- Plant viral vectors for rapid, high-level antigen production
- Encapsulation techniques to protect antigens from gastric degradation
- Multi-antigen expression to create combination vaccines

Future research must focus on large-scale trials, refinement of dosage control, enhancement of immune potency, and robust regulatory frameworks.

CONCLUSION

Plant-based edible vaccines represent a rapidly advancing field with the potential to revolutionize global immunization. They address many limitations of conventional vaccine systems by offering low-cost production, needle-free delivery, and enhanced stability. While challenges remain regarding dosage standardization, biosafety, and regulatory approval, ongoing innovation in plant biotechnology continues to strengthen the feasibility of edible vaccines. With further development and clinical validation, these vaccines can become pivotal tools for reducing infectious disease burden and promoting equitable access to immunization worldwide.

REFERENCES

1. Ma JK, Drake PM, Chargelegue D. Plant-based vaccines: novel and low-cost approaches to immunization. Curr Top Microbiol Immunol.
2. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci.
3. Yusibov V, Rabindran S. Recent progress in the development of plant-derived vaccines. Expert Rev Vaccines.
4. Streatfield SJ. Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnol J.
5. Tacket CO, Mason HS. A review of clinical trials of plant-based oral vaccines. Vaccine.
6. Walmsley AM, Arntzen CJ. Edible vaccines. Curr Opin Biotechnol.
7. Rybicki EP. Plant-made vaccines for humans and animals. Curr Opin Biotechnol.
8. Chan HT, Daniell H. Plant-made oral vaccines against human infectious diseases. Expert Rev Vaccines.
9. Mason HS, et al. Expression of Norwalk virus capsid protein in transgenic plants and its immunogenicity. Proc Natl Acad Sci.
10. Kapila J, et al. Oral immunization with transgenic plants expressing bacterial antigens. Nat Biotechnol.
11. Rosales-Mendoza S. Next-generation plant-based vaccines. Plant Cell Rep.

12. Gomez Lim MA. Plant-based vaccines for the developing world. Curr Opin Biotechnology
13. Stoger E, Ma JK, Fischer R, Christou P. Sowing the seeds of success: pharmaceutical proteins from plants. Curr Opin Biotechnol. 2005;16(2):167–173.
14. Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv. 2009;27(4):449–467.
15. Rybicki EP. Plant-made vaccines for humans and animals. Curr Opin Biotechnol. 2010;21(3): 1–7.
16. Streatfield SJ, Howard JA. Plant-based vaccines. Adv Virus Res. 2003;62:263–313.
17. Daniell H, Rai V, Xiao Y. Cold-chain and virus-free oral vaccines manufactured in lettuce chloroplasts stimulate immune responses against polio. Plant Biotechnol J. 2019;17(7):1357–1368.
18. Rosales-Mendoza S, Soria-Guerra RE, López-Revilla R. Exploiting plant genetic engineering to produce mucosal vaccines. Expert Rev Vaccines. 2016;15(7):1–20.
19. Nochi T, Takagi H, Yuki Y et al. Rice-based oral vaccine induces human immune responses against cholera. Proc Natl Acad Sci USA. 2007;104(23): 8578–8583.
20. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA. 1992;89(24):11745–11749.
21. Yuki Y, Kiyono H. Mucosal vaccines: the promise and challenge of antigen delivery. Nat Rev Immunol. 2003;3: 592–600.
22. Takeyama N, Matsuda Y, Takahashi H. Plant-based vaccines: production and challenges. J Pharm Sci Tech. 2020;74: 243–256.
23. McCormick AA, Reddy S, Reinl SJ et al. Plant-produced rotavirus-like particles: a low-cost vaccine candidate for underdeveloped countries. J Virol. 2003;77: 1–12.
24. Salyaev RK, Rekoslavskaya NI. Edible vaccine: problems and prospects. Biochemistry (Moscow). 2014;79(2): 176–182.
25. Langridge WHR. Edible vaccines. Sci Am. 2000;283: 66–71.
26. Chargelegue D, Drake PM, Obregon P et al. Highly immunogenic and protective recombinant vaccine expression in transgenic plants. Plant Biotechnol J. 2005;3: 1–13.
27. Streatfield SJ. Oral delivery of recombinant proteins in plants. Mol Biotechnol. 2006;32: 79–90.
28. Kapusta J, Modelska A, Figlerowicz M et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999;13: 1796–1799.
29. Rukavtsova EB, Tischenko VK. Edible vaccines: a new approach for immunization. Biotechnol Biotechnol Equip. 2017;31(2): 285–300.
30. Tacket CO. Plant-derived vaccines against diarrheal diseases. Vaccine. 2005;23(15): 1866–1869.
31. Moravec T, Schmidt MA, Herman EM. Production of recombinant proteins in plants. Curr Opin Biotechnol. 2017;49: 101–107.
32. Breen L, Phyo YZ, Akinyemi IA, Adedeji AO. Plant-based edible vaccines in the fight against global infectious diseases: a systematic review. Front Plant Sci. 2022;13: 875321.
33. Clarke JL, Daniell H. Plastid biotechnology for crop production and plant-derived vaccine development. Plant Mol Biol. 2011;76: 161–172.
34. Gómez E, Rosales-Mendoza S. Next-generation plant-based oral vaccines: targeting mucosal immunity. J Immunol Res. 2020;2020: 1–12.
35. Pérez-Filgueira DM, Gómez E, Chauhan M et al. Improving antigen stability and delivery in edible vaccines. Plant Cell Rep. 2019;38: 1105–1118.